Introduction {#S0005}
============

Essential arterial hypertension and hyperlipidaemia are powerful risk factors of cardiovascular disease. Endothelial dysfunction is a leading cause of early development and preservation of arterial hypertension \[[@CIT0001]\]. Endothelial function can be assessed using ultrasound methods to observe the arterial flow-mediated dilation (FMD). It is also possible to assess biomarkers of endothelial function, of which nitric oxide (NO) and endothelin-1 (ET-1) play a crucial role. The increase in ET-1, as well as NO defective endothelial release, is common in hypertensive patients \[[@CIT0001], [@CIT0002]\]. Moreover, it is thought that high blood pressure values are associated with a loss of balance between the status of oxidative stress and the level of antioxidants \[[@CIT0003]\].

Apart from lowering cholesterol, statins demonstrate other biological actions, including anti-inflammatory effects and improved endothelial function. Current data indicate that statins could have an extensive range of indications \[[@CIT0004]\].

Statins interact with blood pressure control in different populations of hypertensive patients \[[@CIT0005]\]. However, the influence of statin therapy on peroxide concentrations as well as total antioxidant status in normolipidaemic hypertensive patients remains unclear.

This study sought to investigate, in a crossover design, the improvement of endothelial dysfunction in normolipidaemic patients with hypertension under treatment, before and after atorvastatin treatment, and to determine whether the alteration of biomarkers assessing endothelial function (NO and ET-1), oxidative stress (measured by Oxystat), or total antioxidative status could be responsible for that effect.

Material and methods {#S0006}
====================

Study population {#S20003}
----------------

Among 92 patients referred to our outpatient clinic with previously diagnosed and treated essential arterial hypertension, we studied 56 (32 males; aged 44 to 64 years) non-smoking, normolipidaemic ones. The mean time of a history of arterial hypertension was 5 ±3.2 years. Patients were randomized in an open-label manner in a 2 : 1 proportion to atorvastatin (80 mg/day/3 months; group A, *n* = 39), or to the standard, previous therapy (group B, *n* = 17), which means that these patients were treated with standard anti-hypertensive agents including angiotensin-converting enzyme inhibitors (ACE-I), diuretics, β-blockers (BB), calcium antagonists (CA) and angiotensin receptor blockers (ARB). The proportion of anti-hypertensive agents was similar between groups. The exact method of randomization and the percentage of antihypertensive agents are described elsewhere \[[@CIT0006]\]. The mean value of total cholesterol for the whole group was 185.2 mg/dl (SD ±38.8). Atorvastatin significantly reduced total cholesterol (TC), low density lipoprotein (LDL) and triglyceride (TG) concentrations \[[@CIT0006]\]. The activities of alanine and aspartate aminotransferases did not significantly change after atorvastatin treatment.

The study was done in a crossover design -- after 3 months, the groups were changed: group A\* and B\*. With this type of study, every patient serves as his or her own control. Blood pressure were measured using a 24-h ambulatory blood pressure measurement device (ABPM, Tracker Reynolds NIBP2, Reynolds Medical, Hertford, UK) as previously described \[[@CIT0006]\]. Basic mean values for systolic and diastolic blood pressures were similar in groups A and B: systolic blood pressure 129 ±11 mmHg vs. 129.5 ±13 mmHg and diastolic blood pressure 76 ±9 mmHg vs. 74 ±7.6 mmHg (*p* = NS).

The study design complied with the Helsinki Declaration of 1975 (revised in 1996), and it was approved by the local institutional committee on human research (Institutional Review Board -- Local Bioethics Committee of Bialystok Medical University). Informed consent of all participants covered by the study was obtained.

Endothelium-dependent FMD was estimated following the instructions given by Corretti and associates \[[@CIT0007]\]. Flow-mediated dilation was determined in both groups at baseline, after 3 months (before crossover), and at the end of the study (3 months after crossover). All participants fasted for 12 h and avoided exercise for 4 to 6 h before FMD examination.

The brachial artery diameter was measured 6 cm above the antecubital space using a high-resolution ultrasound 7.5-MHz linear array transducer (Toshiba SSA-140A). Baseline imaging was followed by 5-min occlusion of arterial flow, achieved by inflating a pneumatic cuff above the antecubital fossa (upper arm occlusion to at least 50 mmHg above systolic blood pressure to occlude arterial flow). After deflating the pneumatic cuff, the brachial artery was imaged continuously for 3 min (reactive hyperaemia and endothelium-dependent dilation). The internal diameter (measured in mm) was defined as the distance between the intima-lumen interface of the near wall and the intima-lumen interface of the far wall, and was assessed during late-diastole corresponding to the R wave of the electrocardiogram (ECG) trace. The maximum diameter was taken into consideration. Flow mediated dilation was expressed as percentage change from rest \[× 100 (brachial artery diameter at peak hyperaemia -- diameter at rest)/diameter at rest\]. Measurements were performed in a blinded manner, without knowledge of the patient\'s group assignment.

Blood sampling and biochemical measurements {#S20004}
-------------------------------------------

Venous blood samples were obtained from fasting patients between 8:00 am and 10:00 am. The patients were lying comfortably in the supine position for 15 min. After that time, an antecubital vein of the non-dominant forearm was cannulated, and after another 20 min, venous blood samples for total antioxidant status, peroxides, NO, and ET-1 assays were collected into tubes with the clotting activation system (tubes for ET-1 were put on ice immediately after collection). All samples were centrifuged within 2 h after drawing and stored at --80°C until assayed.

Serum concentration of total antioxidant status was assayed using an enzymatic method with peroxidase by commercially available RANDOX total antioxidant status kits (Randox, Ardmore, United Kingdom) according to the manufacturer\'s instructions. This method has been described previously \[[@CIT0008]\].

Plasma concentrations of peroxides were measured using Oxystat colorimetric assay kits (Biomedica, Wien, Austria). The results show a direct correlation between free radicals and circulating biological peroxides, and thus allow characterization of the oxidative status in biological samples. The peroxide concentration is determined by the reaction of the biological peroxides with peroxidase and subsequent colour-reaction using tetramethylbenzidine as a substrate. After addition of a stop solution, the coloured liquid is measured photometrically at 450 nm \[[@CIT0009]\]. The intra-assay coefficient of variation is referred to by the manufacturer of assay kits as 3.1% at peroxide mean concentration of 221 µmol/l, SD = 6.9 µmol/l.

Serum levels of NO were measured using colorimetric total NO/nitrite/nitrate assay kits (R&D Systems, Abingdon, England) \[[@CIT0006]\]. The intra-assay CV% is reported by the manufacturer of assay kits as 2.5% at NO mean concentration of 30 µmol, SD = 0.76 U/l.

Serum concentrations of ET-1 were measured using enzyme-linked immunosorbent assay (ELISA) kits (Biomedica, Wien, Austria). The intra-assay coefficient of variation is referred to by the manufacturer of assay kits as 4% at ET-1 mean concentration of 2.02 fmol/ml, SD = 0.08.

Statistical analysis {#S20005}
--------------------

Results are expressed as means ± standard deviation (SD) or 95% confidence interval, CI (variables with the normal distribution) or *n*, percentage, depending on the type of variables. Particular clinical and biochemical parameters were compared using ANOVA for repeated measures for principal factors or recurrent measurements and a χ^2^ test. All analyses were done using Statistica 9.1 PL. Value of *p* below 0.05 was considered statistically significant.

Results {#S0007}
=======

Baseline clinical and biochemical characteristics of the study patients are shown in [Table I](#T0001){ref-type="table"}. Atorvastatin, added to the existing therapy for 3 months, decreased blood pressure values in both groups -- in group A: systolic blood pressure --5.7 mm Hg (95% confidence interval (CI) --4.1 mmHg to --7.2 mmHg) and diastolic blood pressure --3.9 mmHg (95% CI --2.7 mmHg to --5.0 mmHg), and in group B\*: systolic blood pressure --1.23 mmHg (95% CI --6.93 to 4.46) and diastolic blood pressure --2.0 mmHg (95% CI --5.46 to 1.46) ([Figure 1](#F0001){ref-type="fig"}).

![Changes in systolic and diastolic blood pressure values in groups A-A\* and B-B\* *SBP -- systolic blood pressure, DBP -- diastolic blood pressure*](AMS-7-18044-g001){#F0001}

###### 

Baseline clinical and biochemical characteristics of study patients

  Parameter                         Group A (*n* = 39)   Group B (*n* = 17)   Value of *p*
  --------------------------------- -------------------- -------------------- --------------
  Age, mean ± SD \[years\]          52.5 ±14.7           47.9 ±18.1           0.31
  Sex, males \[%\]                  43                   53                   0.49
  ATS, mean ± SD \[mmol/l\]         1.5 ±0.2             1.4 ±0.3             0.9
  Peroxides, mean ± SD \[µmol/l\]   326.8 ±194.3         249.1 ±139.8         0.05
  NO, mean ± SD \[IU/l\]            22.6 ±14.2           39.9 ±29.5           0.4
  ET-1, mean ± SD \[fmol/ml\]       1.32 ±2.2            0.5 ±0.2             0.14

SD -- standard deviation, TAS -- total antioxidant status, NO -- nitric oxide, ET-1 -- endothelin-1

Flow-mediated dilation showed significant improvement in group B\* (from 11.9 ±8.3% to 22.1 ±9.0%; *p* \< 0.05), but was not significant in group A (from 18.7 ±8.9% to 19.6 ±12.6%; *p* = 0.7) ([Figure 2](#F0002){ref-type="fig"}). However, in group A\* (after crossover), systolic blood pressure values significantly increased (*p* = 0.02) and FMD significantly decreased (from 19.6 ±12.6% to 13.0 ±10.5%; *p* \< 0.05) ([Figures 1](#F0001){ref-type="fig"} and 2).

![Flow-mediated dilation changes in both groups during the study *FMD -- flow-mediated dilation*](AMS-7-18044-g002){#F0002}

In an ANOVA test, in patients with FMD improvement after atorvastatin treatment, there was a trend to a greater blood pressure reduction -- in group A (before crossover): systolic blood pressure --7.2 mmHg (95% CI --10.75 to --3.62) and diastolic blood pressure --4.8 mmHg (95% CI --6.85 to --2.78) and a significant blood pressure reduction in group B\* (after crossover): systolic blood pressure --3.1 mmHg (95% CI --9.91 to --3.75) and diastolic blood pressure --2.4 mmHg (95% CI --6.68 to --1.91) ([Figure 3](#F0003){ref-type="fig"}).

![Changes in SBP and DBP values in patients with FMD improvement (ANOVA test) SBP -- systolic blood pressure, DBP -- diastolic blood pressure, FMD -- flow-mediated dilation](AMS-7-18044-g003){#F0003}

In group A, FMD improvement and aggravation were not associated with significant changes (the increase) in total antioxidant status concentrations: mean 0.04 mmol/l (95% CI --0.91 to 0.18) and 0.02 mmol/l (95% CI --0.10 to 0.13) ([Figure 4](#F0004){ref-type="fig"}). Also, in that group of patients, neither FMD improvement nor impairment was associated with significant changes in Oxystat (decrease: mean --64.1 µmol/l (95% CI --183.9 to 55.7) and increase: mean 9.6 µmol/l (95% CI --103.8 to 123.0), respectively) ([Figure 4](#F0004){ref-type="fig"}).

![FMD changes in relation to TAS and Oxystat concentrations in group A patients (all p = NS) FMD -- flow-mediated dilation, TAS -- total antioxidant status, Oxystat -- a method to measure peroxide concentrations](AMS-7-18044-g004){#F0004}

In group B\* (receiving statin after crossover), patients with FMD improvement had a trend to an increase in NO concentrations (mean 2.7 IU/l (95% CI --5.34 to 10.91)) and decrease in ET-1 values (mean --0.2 fmol/ml \[95% CI --0.41 to 0.06\]) ([Figure 5](#F0005){ref-type="fig"}). In patients without FMD improvement, NO decreased (mean --17.0 IU/l \[95% CI --46.30 to 12.26\]), whereas ET-1 increased (mean 0.02 fmol/ml (95% CI --0.82 to 0.86)) ([Figure 5](#F0005){ref-type="fig"}). However, these trends were not significant.

![FMD changes in relation to NO and ET-1 concentrations in group B\* patients (all *p* = NS) *FMD -- flow-mediated dilation, NO -- nitric oxide, ET-1 -- endothelin-1*](AMS-7-18044-g005){#F0005}

Discussion {#S0008}
==========

The results of this study suggest that the hypotensive effect of atorvastatin is related to FMD improvement in a selected group of hypertensive patients. Two actions could be responsible for this antihypertensive effect: FMD variation probably depends on concentration changes in oxidative stress/antioxidants as well as changes in biomarkers of endothelial function (NO, ET-1).

Data have emerged that endothelial dysfunction is an early step in developing atherosclerosis and is characterized mainly by a reduction in the bioavailability of NO \[[@CIT0010]\]. Endothelial function is often quantified by FMD, which represents the endothelium-dependent vasorelaxation of the brachial artery, owing to increased blood flow \[[@CIT0007], [@CIT0011]\]. We showed the validity of the measurement of endothelial dysfunction using the FMD approach in a selected group of normolipidaemic, treated hypertensive patients.

Because endothelial dysfunction plays a significant role in the pathogenesis of arterial hypertension, it is reasonable to search for new strategies aimed at improving endothelial function \[[@CIT0012]\]. Several studies indicate that statins could influence blood pressure control in various hypertensive patients \[[@CIT0005]\]. This is a pleiotropic statin effect, i.e. independent of lipid-lowering \[[@CIT0013]\].

Still, the hypotensive effect of statin seems to be ambiguous \[[@CIT0013]\]. Koh *et al.* in their review article interpret various animal and clinical studies regarding the blood pressure lowering statin effect. The variety of results could be related to various blood pressure measurement techniques and various statins used, small sample size study populations, confounding effects of concomitant anti-hypertensive therapy, various criteria, different comparative groups and, finally, various populations studied. It has been observed that statins lower blood pressure values in patients with elevated, but not normal blood pressure regardless of cholesterol level \[[@CIT0013]\]. These results have been confirmed by Borghi *et al*. in the Brisighella Heart Study -- a large randomized controlled trial \[[@CIT0014]\]. Among 1356 patients with hypercholesterolaemia, a significant decrease in blood pressure was observed in the two upper quartiles of systolic blood pressure (≥ 140 mmHg) and was greater in patients treated with statins. Thus, it has been suggested that statins significantly lower blood pressure in patients with uncontrolled hypertension, but not in patients with controlled hypertension or normotension \[[@CIT0013]\]. Moreover, in the CAFE-LLA (The Conduit Artery Function Evaluation-Lipid-Lowering Arm) -- a substudy of an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) -- 891 patients with hypertension were randomized to atorvastatin 10 mg daily or placebo. Statin therapy did not influence central aortic blood pressure or haemodynamics \[[@CIT0015]\]. The results of PHYLLIS (Plaque Hypertension Lipid-Lowering Italian Study) -- a randomized double blind trial -- confirmed that the addition of pravastatin to anti-hypertensive treatment did not cause a reduction in systolic and diastolic blood pressure values in patients with low blood pressure at baseline (clinic systolic 160 mmHg, 24-h systolic 137 mmHg; clinic diastolic 98 mmHg and 24-h diastolic 85 mmHg) \[[@CIT0016]\].

However, in the previous study, we confirmed the hypotensive effect of atorvastatin in normolipidaemic patients with already treated and well-controlled essential arterial hypertension. What is more, we investigated the influence of statin therapy on various biomarkers which are involved in the pathogenesis of essential arterial hypertension \[[@CIT0006]\]. We discovered that in statin-treated patients the decrease in blood pressure was correlated with the increase in NO and the decrease in autoantibodies against oxidized LDL (ox-LDL).

In the current study, we aimed to investigate the influence of statin treatment on FMD and intended to assess what the blood pressure would be after stopping atorvastatin therapy. A high dose of atorvastatin decreased blood pressure values and a greater reduction was concurrent with FMD improvement. Conversely, after suspending statin therapy, systolic blood pressure values significantly increased, which was consistent with FMD impairment. Bellia and associates showed that simvastatin significantly improved FMD to a greater extent than rosuvastatin. However, no association between FMD improvement, low-density lipoprotein cholesterol (LDL) reduction, and changes in high-sensitivity C-reactive protein (hs-CRP) levels were found \[[@CIT0017]\]. In our study, we assessed biomarkers of oxidative stress, antioxidative status and endothelial dysfunction, and failed to demonstrate significant relations between them and FMD variation. Based on recent data, we presumed to intensify the investigations. We wanted to find the link between the hypotensive effect of statin, FMD improvement, and changes in concentrations of biomarkers in essential hypertensive patients.

A reduction of NO and an increase in ET-1 secretions have been observed in hypertensive patients \[[@CIT0002], [@CIT0018]\]. Moreover, several diseases, including hypertension, have been proved to be related to oxidative stress and production of free radicals. It has been suggested that high blood pressure is a state associated with a loss of the balance between pro-oxidation and antioxidation \[[@CIT0003]\]. Increased levels of peroxides and decreases in antioxidants in patients with essential arterial hypertension have been reported earlier \[[@CIT0018]\]. However, to our knowledge, changes in these agents in the aspect of FMD improvement or impairment after statin therapy have not been investigated previously. In our patients, FMD improvement was related to a trend towards increase in total antioxidant status, which was less evident, but still present, after the withdrawal of statin therapy (in patients with FMD impairment). This may suggest a lasting antioxidant statin effect.

Simultaneously, FMD improvement was related to the decrease in peroxide concentration (measured by Oxystat) and FMD impairment was related to its increase. In the same way, NO and ET-1 concentration changes were observed: vasodilatative NO tended to increase and vasoconstrictive ET-1 to decrease after statin therapy, and these effects were consistent with FMD improvement.

We chose a selected group of treated, normolipidaemic patients and added to that treatment a high dose of atorvastatin. There are some data proving that a low dose of atorvastatin could have pleiotropic effects. Kuryata and Yegorova demonstrated an improvement in endothelial function assessed by FMD in patients with coronary artery disease treated with atorvastatin 10 mg daily for 12 weeks \[[@CIT0019]\]. Administration of a statin in hypertensive patients with blood pressure values effectively reduced by traditional anti-hypertensive agents does not have an additional blood pressure lowering effect \[[@CIT0013]\]. Thus, we wanted to use a higher dose of atorvastatin to have a better potential effect in treated hypertensives.

Some studies found no change in blood pressure levels with additional statin treatment in patients with controlled hypertension by angiotensin-converting enzyme inhibitors and calcium antagonists or atenolol. The addition of simvastatin to losartan did not enhance the blood pressure lowering action of losartan in hypertensive and hypercholesterolaemic patients \[[@CIT0020]\]. The antihypertensive effect of captopril and atenolol was not influenced by concurrent administration of pravastatin \[[@CIT0021]\]. In hypertensive, hypercholesterolaemic patients, pravastatin remains efficacious as a lipid-lowering agent in the presence of antihypertensive therapy (angiotensin-converting enzyme inhibitors and calcium antagonists), but does not enhance the blood pressure lowering action of these drugs \[[@CIT0022]\]. However, the results of one study demonstrate that the use of statins in combination with anti-hypertensive drugs can improve blood pressure control in patients with uncontrolled hypertension and high serum cholesterol levels \[[@CIT0023]\]. The changes in blood pressure values in our studied hypertensive patients with previous optimal anti-hypertensive treatment and with a normal lipid profile after 3 months of high-dose atorvastatin treatment could be explained by such a synergy with other drugs. Ge *et al.* have shown that atorvastatin added to amlodipine, apart from inhibition of the inflammatory process and reduction of left ventricular hypertrophy, markedly decreased systolic and diastolic blood pressure values as compared to amlodipine alone \[[@CIT0024]\].

Our hypertensive patients, besides well-controlled diseases, were normolipidaemic. In the previous report, we revealed that the hypotensive effect of atorvastatin in properly treated patients is independent of lipid-lowering \[[@CIT0006]\]. To avoid methodological limitations, a selected group of homogeneous patients was studied. The study was prospective, randomised and had a cross-over design. To assume that both groups of patients received a comparable proportion of anti-hypertensive agents, group B was created to prove the potential hypotensive effect of atorvastatin in group A. Also, in contrast to previous studies, we used ABPM. Available data are largely limited to blood pressure values measured in the clinic without providing information on ambulatory blood pressure, which is of greater prognostic importance \[[@CIT0025]--[@CIT0027]\]. Finally, we examined young hypertensive patients, and available data provide information that, at least in patients with metabolic syndrome, FMD changes were observed in the elderly \[[@CIT0028]\].

In conclusion, the present data demonstrate that the hypotensive effect of atorvastatin is related to FMD improvement in normolipidaemic hypertensive patients with previously diagnosed and treated disease. Thus, there may be a link between atorvastatin action and improvement in endothelial function.

The main limitation of this study is the small number of patients. This might be the reason for trends -- not significant changes -- in some of the parameters assessed. However, there are studies assuming the same issue, but investigating even smaller groups of patients \[[@CIT0029]\]. Since higher baseline systolic and diastolic blood pressure values could also influence the results, it is hard to compare these studies. Patients with high blood pressure levels at baseline as well as those treated with angiotensin-converting enzyme inhibitors and calcium channel blockers are expected to benefit more in this regard \[[@CIT0030]\]. Furthermore, the differences in baseline levels of peroxides, endothelin and NO between the two groups were quite big; this could have also influenced the results. Perhaps it would be more interesting to compare different doses of the same statin, or different statins (particularly those commonly used -- simvastatin, atorvastatin and rosuvastatin). However, our study sought to examine a selected group of hypertensive patients. Moreover, we used a prospective cross-over design to increase the statistical power of the study. Treatment with statins during the studies that reported blood pressure data ranged from 1 to 12 months. A short time of statin treatment could probably influence biochemical results. However, the patients were followed prospectively and were investigated thoroughly; therefore, the authors consider the obtained results as being representative.
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